Short Interest in First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Drops By 41.7%

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was the recipient of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 700 shares, a decline of 41.7% from the January 31st total of 1,200 shares. Based on an average daily trading volume, of 2,800 shares, the short-interest ratio is currently 0.3 days.

Institutional Investors Weigh In On First Trust Nasdaq Pharmaceuticals ETF

Several hedge funds and other institutional investors have recently made changes to their positions in the company. LPL Financial LLC increased its stake in First Trust Nasdaq Pharmaceuticals ETF by 9.3% in the fourth quarter. LPL Financial LLC now owns 55,876 shares of the company’s stock worth $1,507,000 after purchasing an additional 4,776 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of First Trust Nasdaq Pharmaceuticals ETF by 17.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 16,403 shares of the company’s stock worth $442,000 after purchasing an additional 2,384 shares during the period. Summit Investment Advisors Inc. boosted its position in First Trust Nasdaq Pharmaceuticals ETF by 13.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,173 shares of the company’s stock valued at $382,000 after acquiring an additional 1,633 shares in the last quarter. Finally, Vivaldi Capital Management LP increased its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 15.6% in the 4th quarter. Vivaldi Capital Management LP now owns 8,677 shares of the company’s stock valued at $243,000 after acquiring an additional 1,171 shares during the period.

First Trust Nasdaq Pharmaceuticals ETF Price Performance

Shares of NASDAQ FTXH traded up $0.25 during mid-day trading on Friday, hitting $28.11. 1,888 shares of the company’s stock traded hands, compared to its average volume of 3,254. The company’s 50-day moving average is $27.41 and its two-hundred day moving average is $28.13. First Trust Nasdaq Pharmaceuticals ETF has a 1 year low of $25.73 and a 1 year high of $29.72. The company has a market capitalization of $14.06 million, a P/E ratio of 15.98 and a beta of 0.70.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The business also recently announced a dividend, which was paid on Tuesday, December 31st. Stockholders of record on Friday, December 13th were given a dividend of $0.1304 per share. The ex-dividend date of this dividend was Friday, December 13th. This is an increase from First Trust Nasdaq Pharmaceuticals ETF’s previous dividend of $0.13.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.